Details of 308 molecular probes obtained in 223 patients
| Probe type and sensitivity . | First probe, 223 patients, no. . | Second probe, 85 patients, no. . | Total probes,no. (%) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 10−5 . | 10−4 . | 10−3 . | Total . | 10−5 . | 10−4 . | 10−3 . | Total . | ||
| IgH/TCR rearrangements | |||||||||
| IgH | 25 | 14 | 1 | 40 | 6 | 7 | 3 | 16 | 56 (18.2) |
| Ig—kappa | 2 | 5 | 1 | 8 | 3 | 5 | — | 8 | 16 (5.2) |
| TCRD | 14 | 15 | 4 | 33 | 5 | 14 | 4 | 23 | 56 (18.2) |
| TCRB | 5 | 6 | — | 11 | 6 | 7 | — | 13 | 24 (7.8) |
| TCRG | 22 | 15 | 7 | 44 | 2 | 10 | 13 | 25 | 69 (22.4) |
| Fusion genes | |||||||||
| BCR-ABL | 61 | — | — | 61 | — | — | — | — | 61 (19.8) |
| MLL-AF4 | — | 20 | — | 20 | — | — | — | — | 20 (6.5) |
| E2A-PBX1 | 5 | — | — | 5 | — | — | — | — | 5 (1.6) |
| SIL-TAL1 | — | 1 | — | 1 | — | — | — | — | 1 (0.3) |
| Total (%) | 134 (60) | 76 (34) | 13 (6) | 223 (100) | 22 (25.9) | 43 (50.6) | 20 (23.5) | 85 (100) | 308 (100) |
| Probe type and sensitivity . | First probe, 223 patients, no. . | Second probe, 85 patients, no. . | Total probes,no. (%) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 10−5 . | 10−4 . | 10−3 . | Total . | 10−5 . | 10−4 . | 10−3 . | Total . | ||
| IgH/TCR rearrangements | |||||||||
| IgH | 25 | 14 | 1 | 40 | 6 | 7 | 3 | 16 | 56 (18.2) |
| Ig—kappa | 2 | 5 | 1 | 8 | 3 | 5 | — | 8 | 16 (5.2) |
| TCRD | 14 | 15 | 4 | 33 | 5 | 14 | 4 | 23 | 56 (18.2) |
| TCRB | 5 | 6 | — | 11 | 6 | 7 | — | 13 | 24 (7.8) |
| TCRG | 22 | 15 | 7 | 44 | 2 | 10 | 13 | 25 | 69 (22.4) |
| Fusion genes | |||||||||
| BCR-ABL | 61 | — | — | 61 | — | — | — | — | 61 (19.8) |
| MLL-AF4 | — | 20 | — | 20 | — | — | — | — | 20 (6.5) |
| E2A-PBX1 | 5 | — | — | 5 | — | — | — | — | 5 (1.6) |
| SIL-TAL1 | — | 1 | — | 1 | — | — | — | — | 1 (0.3) |
| Total (%) | 134 (60) | 76 (34) | 13 (6) | 223 (100) | 22 (25.9) | 43 (50.6) | 20 (23.5) | 85 (100) | 308 (100) |